Trial Profile
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-1439 (Doravirine) in Subjects With Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Doravirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 11 Jun 2018 Results accessing impact of renal impairment on Doravirine pharmacokinetics has been published in the Antimicrobial Agents and Chemotherapy
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 27 Dec 2016 Results published in the Journal of Clinical Pharmacology